ClearPoint Neuro, Inc.
NASDAQ:CLPTMedical - Devices
+$0.89 today
- Market cap
- $247.14M
- Beta
- 1.31
- P/E (TTM)
- -18.0
- EPS (TTM)
- -$0.98
Volume 0.64M
Average 0.67M
CLPT Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
ClearPoint Neuro, Inc.NASDAQ: CLPT
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents rises 187.3% from a year ago
Cash & equivalents stood at $35.59M at the end of Q1 FY2026, up 187.3% from a year earlier and down 22.5% from the prior quarter. Over 3 fiscal years it compounded at +18.5% a year.
Context
- Cash & equivalents amounted to 38.1% of total assets at the end of Q1 FY2026, down 3.1 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +187.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 45.92M USD
- Year-over-year change
- +128.4%
- 4-year CAGR
- -4.0%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 45.92M | +128.4% |
| FY2024 | 2024-12-31 | 20.1M | -13.1% |
| FY2023 | 2023-12-31 | 23.14M | -16.2% |
| FY2022 | 2022-12-31 | 27.62M | -49.0% |
| FY2021 | 2021-12-31 | 54.11M | — |
Cash & Equivalents vs competitors
How CLPT compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +187.3% is the highest of 10, against a peer median of +5.7%.
- Cash & equivalents amounts to 38.1% of total assets for CLPT, versus a peer median of 14.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $466.01M USD | +79.2% | +1.5% | 87.6% | |
| Mar 2026 | $265.77M USD | +76.1% | +13.3% | 41.6% | |
| Mar 2026 | CA$233.36M CAD | +5.7% | -0.8% | 17.8% | |
| Mar 2026 | $162.64M USD | +43.5% | +26.9% | 44.9% | |
| Mar 2026 | $120.28M USD | +107.5% | +17.4% | 13.6% | |
| Apr 2026 | $85.3M USD | -58.4% | +17.5% | 7.8% | |
| Mar 2026 | $65.67M USD | -31.1% | -32.6% | 14.6% | |
| Mar 2026 | $65.6M USD | -32.4% | -11.1% | 6.2% | |
| Mar 2026 | $35.59M USD | +187.3% | +18.5% | 38.1% | |
| Mar 2026 | $33.54M USD | -18.6% | +26.8% | 13.8% | |
| Peer median (excluding CLPT) | — | +5.7% | +13.3% | 14.6% | |
Competitors are the stored peer set for CLPT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 54.11M | 27.62M | 23.14M | 20.1M | 45.92M |
| Short-term Investments | 0 | 9.87M | 0 | 0 | 0 |
| Net Receivables | 2.34M | 2.67M | 3.94M | 4.71M | 7.26M |
| Inventory | 4.94M | 9.3M | 7.91M | 6.86M | 8.36M |
| Other Current Assets | 0 | 1.72M | 0 | 1.68M | 2.06M |
| Total Current Assets | 61.89M | 51.18M | 36.17M | 33.36M | 63.6M |
| Property, Plant & Equipment (Net) | 2.78M | 2.7M | 4.95M | 5.09M | 11.05M |
| Goodwill | 0 | 0 | 0 | 0 | 7.47M |
| Intangible Assets | 265K | 1.03M | 1.04M | 484K | 13.92M |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 644K | 581K | 495K | 251K | 1.7M |
| Total Non-current Assets | 3.69M | 4.31M | 6.49M | 5.83M | 34.15M |
| Total Assets | 65.58M | 55.49M | 42.66M | 39.19M | 97.75M |
| Account Payables | 427K | 272K | 393K | 1.34M | 1.26M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 678K | 1.07M | 2.61M | 2.12M | 1.67M |
| Other Current Liabilities | 2.6M | 2.82M | 2.95M | 4.89M | 4.36M |
| Total Current Liabilities | 4.75M | 6.79M | 7.43M | 10.35M | 10.77M |
| Long-term Debt | 9.84M | 9.89M | 9.95M | 0 | 49.08M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 354K |
| Deferred Revenue (Non-current) | 264K | 390K | 541K | 436K | 581K |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 489K |
| Total Non-current Liabilities | 12.04M | 11.82M | 14.06M | 3.45M | 58.96M |
| Total Liabilities | 16.79M | 18.6M | 21.49M | 13.8M | 69.73M |
| Common Stock | 237K | 246K | 247K | 276K | 294K |
| Retained Earnings | (133.93M) | (150.37M) | (172.46M) | (191.37M) | (216.91M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 5.64M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 48.79M | 36.89M | 21.17M | 25.39M | 28.02M |
| Total Debt | 12.28M | 11.99M | 13.94M | 3.57M | 58.23M |
| Net Debt | (41.83M) | (15.63M) | (9.2M) | (16.54M) | 12.31M |
ClearPoint Neuro, Inc.
NASDAQ:CLPT
Intrinsic Alpha fair value
Locked
Current Price
$7.71
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.